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Background: Inflammatory cytokines in the colonic microenvironment have been shown to increase with advance
colorectal cancer disease state. However, the contribution of inflammatory cytokines to pre-malignant disease, such
as the formation of adenomas, is unclear.
Methods: Using the Milliplex® MAP Human Cytokine/ Chemokine Magnetic Bead Panel Immunoassay, serum
cytokine and chemokine profiles were assayed among participants without an adenoma (n = 97) and those with an
adenoma (n = 97) enrolled in the NCI-funded Insulin Resistance Atherosclerosis Colon Study. The concentrations of
interleukin-10 (IL-10), IL-1β, IL-6, IL-17A, IL-2, IL-4, IL-7, IL-12(p70), interferon-γ (IFN-γ), macrophage chemoattractant
protein-1 (MCP-1), regulated on activation, normal T cell expressed and secreted (RANTES), tumor necrosis factor-alpha
(TNF-α), vascular endothelial growth factor (VEGF), granulocyte macrophage colony-stimulating factor (GM-CSF), and
macrophage inflammatory protein-1β (MIP-1β) were determined. Multiple logistic regression analyses were used to
evaluate the association between adenoma prevalence and cytokine levels.
Results: The presence of colorectal adenomas was not associated with significant increases in the systemic levels of
proinflammatory (TNF-α, IL-6, IL-1β) or T-cell polarizing (IL-12, IL-2, IL-10, IL-4, IL-17, IFN-γ) cytokines. Furthermore, MCP-1
and RANTES levels were equivalent in the serum of study participants with and without adenomas.
Conclusions: These findings suggest colorectal adenoma prevalence may not be associated with significant alterations
in systemic inflammation.
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Colorectal cancer (CRC) is the second leading cause of
cancer-related deaths in the United States, and the preva-
lence of CRC is increasing worldwide [1,2]. As with most
cancers, CRC results from a combination of genetic and
environmental factors [3]. Colorectal adenomas and polyps
are an early pre-malignant precursor and usually develop
10 years prior to carcinomas [4,5]. Known risk factors* Correspondence: Curtis.Henry@ucdenver.edu
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unless otherwise stated.associated with adenomatous polyp development include
age, smoking, excessive alcohol consumption, obesity, and
chronic inflammatory conditions such as inflammatory
bowel disease (IBD) [4-6]. Consequently, inflammation has
long been suspected to be a major environmental risk fac-
tor in CRC development [7-9]. Other evidence supporting
the link between inflammation and CRC development
comes from the effect of non-steroidal anti-inflammatory
drugs (NSAIDs), particularly aspirin, which has been
shown to reduce CRC incidence and disease progression
[10-13]. More recently, variations in immune cell popula-
tions and changes in the gut microbiome have been linked
to CRC induction and progression [3,14-20]. While
changes such as alterations of the gut microbiome could
potentially be used in risk assessment, currently there areThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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disease states apart from detection of adenomas [21].
It is widely accepted that inflammation plays a major
role in advanced stage CRC disease progression; however,
whether it is associated with the formation of pre-
malignant lesions is currently unclear. Evidence pointing
towards inflammation promoting disease progression from
pre-malignant adenomatous polyps to advance staged
CRC is suggested by the observation that plasma levels of
tumor necrosis factor-alpha (TNF-α), interferon-gamma
(IFN-γ)-induced protein 10, and IL-8 increase in patients
during each stage of disease progression [22]. Similar re-
sults were observed in a mouse model of ulcerative colitis
in which the production of the pro-inflammatory cyto-
kines, chemokines, and M2 macrophages increase as the
disease progressed from dysplasia to CRC metastasis [23].
Furthermore, colorectal adenomas were found to be more
frequent in patients with high endotoxin levels (which
promotes the production of pro-inflammatory cytokines)
at the time of colonoscopy [3]; however, systemic (plasma)
and local (rectal mucosa) cytokine levels were not signifi-
cantly altered in individuals with adenomas relative to
control populations [3]. The correlation between systemic
cytokine levels and adenoma status was also addressed in
studies determining the role of anti-inflammatory dietary
flavonols in colorectal adenoma incidence and prevention
[24,25]. In these studies, high levels of flavonol consump-
tion correlated with decreased serum IL-6 levels and re-
duced adenoma recurrence [25]; however, overall cytokine
profiles were not accurate predictors of flavonol con-
sumption or adenoma incidence [24]. Similarly, an-
other study assaying serum profiles between participants
with colorectal adenomas, predisposing conditions such as
IBD, and those with advanced-stage colon cancer observed
that cytokine profiles could only accurately distinguish
active IBD populations from those with CRC whereas
the profiles between individuals with adenomas and
CRC were not reliable enough to distinguish these two
cohorts [7].
Unlike advanced stage CRC, studies linking inflam-
mation to the presence or development of pre-
malignant lesions are inconsistent. A potential reason
for these inconsistencies could be attributed to the in-
herent degradation of serum cytokines and chemokines
in studies assaying the relationship between disease state
and altered systemic inflammation [26,27]. Based on the
observations that inflammation is increased with advanced
stage CRC, we hypothesized that this would also be the
case when colorectal adenomas are detectable. Therefore,
the aim of our study was to determine if inflammation
was increased in study participants with colorectal ad-
enomas relative to control participants using a novel
methodology based on the stability of interleukin-7
(IL-7) in serum samples. This approach significantlyreduces the inclusion of degraded samples in our study




A case-control study was conducted as part of a multi-
center, multiethnic, prospective cohort study called the
Insulin Resistance Atherosclerosis Study (IRAS), which
was originally designed to investigate the association be-
tween insulin resistance and atherosclerosis. Details of
the design and recruitment have been published previ-
ously [28,29]. Briefly, 1,625 participants consisting of
men and women of non-Hispanic White, Hispanic, and
African American race/ethnicity and various glucose tol-
erance status (normal, impaired glucose tolerance, and
diabetes) were recruited between 1992–1994 from four
clinical sites (Los Angeles, CA; Oakland, CA; San Luis
Valley, CO; San Antonio, TX). Of the original 1,625 par-
ticipants, 600 participants received colonoscopies, and
biopsy specimens were examined between 2002 and
2004 [29]. Participants were recruited for a colonoscopy
if they were ≥50 years of age, able to provide informed
consent, able to undergo the colonoscopy procedure,
and/or likely to benefit from colorectal screening. Partic-
ipants with a prior screening were only included if the
timing of their subsequent surveillance colonoscopy
exam was within the study period. The Internal Review
Boards and ethics committees of all participating institu-
tions including the University of Colorado Anschutz
Medical Campus (Aurora, CO, USA), Kaiser Permanente
(Oakland, CA, USA), the University of Texas Health
Science Center (San Antonio, Texas, USA), Wake For-
est University School of Medicine (Winston-Salem,
NC, USA), and the University of California Los
Angeles (Los Angeles, CA, USA) approved this study.
Written informed consents were obtained from all
study participants prior to any research procedures be-
ing performed.
For this study, 97 participants with adenomas were se-
lected and 97 corresponding participants with normal
colonoscopies from the same clinical site were included
as controls. All participants also needed to have had a
stored serum sample, taken at the time of the colonos-
copy, available for cytokine analyses.
Blood samples were collected following a 12 hour fast
of the participants. Red top tubes were used to collect
the stored serum samples used for cytokines. These sam-
ples were collected, processed, shipped to a central loca-
tion, and stored at -70°C. In 2008, all samples were
shipped by overnight delivery on dry ice to the Univer-
sity of Colorado Anschutz Medical Campus where they
were immediately stored at -80°C until they were ana-
lyzed for cytokine concentrations in 2013.
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Self-reported demographics, smoking practices, NSAID
use within the past 2 weeks, and previous screening his-
tory were collected through interviewer-administrated
questionnaires. Data were collected at baseline (1992–
94), the second visit (1997–1999) and at the colonoscopy
visit (2002–2004). Trained staff collected anthropomet-
ric measures of heights measured to the nearest 0.01 cm
and weights measured to the nearest 0.1 kg. Glucose sta-
tus was determined using a 2-hour, 75-g oral glucose tol-
erance test with cutoff values based on World Health
Organization criteria [30].
Cytokine analysis
Cytokine profiles were determined using the Human
Cytokine/ Chemokine Magnetic Bead Panel protocol from
the Milliplex® Map Kit (Cat. No. HCYTOMAG-60K,
Billerica, MA). Briefly, cytokine/chemokine assay plates
were washed with wash buffer, sealed, and mixed on an or-
bital plate shaker for 10 minutes at room temperature.
The wash buffer was decanted and the standards, assay
buffer, or serum samples were mixed with serum matrix in
each well. After the addition of the samples or controls,
samples were incubated overnight at 4°C on an orbital
shaker with fluorescently-labeled capture antibody-coated
beads. After overnight incubation with capture antibodies
to detect IFN-γ, IL-10, IL-1β, IL-6, MCP-1 (macrophage
chemoattractant protein-1), RANTES (regulated on acti-
vation, normal T cell expressed and secreted), TNF-α,
VEGF, GM-CSF, IL-17A, IL-2, IL-4, MIP-1β (macrophage
inflammatory protein-1β), IL-7, and IL-12(p70), well con-
tents were removed via the washing instructions provided
by the protocol. Biotinylated detection antibodies were
then added to the wells and incubated with samples for 1
hour at room temperature while shaking. After incubation,
well contents were removed as previously described and
streptavidin-phycoerythrin was added to each well. The
samples were incubated with streptavidin-phycoerythrin
for 30 minutes at room temperature. After the incubation
period, samples were washed as previously described and
resuspended in Sheath Fluid. Plates were run on the Lumi-
nex MagPix® machine and data were collected using the
Luminex xPONENT® software (v. 4.2). Analysis of the
cytokine/ chemokine median fluorescent intensity (MFI)
was performed using the Milliplex® Analyst software (v. 5.1).
The interassay coefficient of variation for all cytokines tested
was 11.93%.
Quality control
Degradation is an inherent issue with studies designed
to analyze cytokines and chemokines from thawed
serum or plasma samples [26,27]. To account for this
problem and to increase the validity of our study, we
omitted samples which contained interleukin-7 (IL-7)levels below the limit of detection. This approach was
chosen because IL-7 is a homeostatic cytokine that regu-
lates lymphocyte levels and thus should be detectable in
the serum of most samples [31]. Furthermore, recent
studies have shown that IL-7 is a stable cytokine that
can be reliably detected from thawed serum samples
after multiple freeze thaws [26,27]. Based on our ap-
proach, one-third of our original samples did not meet
the IL-7 positive criteria and were therefore not included
in the final cytokine analysis due to potential degrad-
ation issues which would confound the interpretation of
the results (data not shown).
Statistical analysis
The outcome variable of adenoma status was determined
by the highest grade lesion identified. Those participants
classified as “any adenoma” included participants with an
advanced adenomatous polyp (n = 31) defined those
polyps with villous or mixed tubulovillous features with
high-grade dysplasia or >1 cm in diameter and those par-
ticipants with a non-advanced adenomatous polyp
(n = 66) defined as tubular histology under 1 cm in diam-
eter. None of the polyps had carcinoma. Information was
not collected on whether the polyps were serrated. Con-
trol participants without an adenoma had no polyps, in-
cluding hyperplastic polyps.
Cytokines were categorized into three groups (low,
medium, and high) based on the distributions among those
participants without any adenomas. For ten of the cyto-
kines (GM-CSF, IFN-γ, IL-10, IL-12p70, IL-17A, IL-1β, IL-
2, IL-4, IL-6, and VEGF), the lowest category included
those participants with a cytokine level below detectable
levels. The other two categories were determined based on
the cutoff values of the median in the control group. For
the MCP-1, MIP-1β, TNF-α, IL-7, and RANTES, there
were no (RANTES) or a minimal number of serum sam-
ples with levels of these cytokines below the detectable
level (MCP-1, n = 1; and MIP-1β, n = 4); therefore, tertiles
were generated for each cytokine based on their distribu-
tion in the control group. Based on standard criteria, body
mass index (BMI) was calculated (kg/m2) and categorized
as normal (<25 kg/m2), overweight (25 to >30 kg/m2), and
obese (≥30 kg/m2) [29].
Chi-squared tests were used to evaluate differences be-
tween participants with and without an adenoma by cat-
egorical variables of study center, sex, age, race/ethnicity,
glucose tolerance status at the first visit, BMI at colonos-
copy visit, smoking status, previous screening, NSAID
use within the previous 2 weeks of the colonoscopy visit.
Variables that were significant at p ≤ 0.10 in the bivariate
analysis were included in the multivariate analyses which
included age, sex, and previous screening. Multivariate
unconditional logistic regression was used to evaluate
the association between adenoma prevalence and the
Table 1 Prevalence of colorectal adenoma by
demographic characteristic and risk factors among a









San Antonio, TX 26 (50.0) 26 (50.0) 1.00
San Luis Valley, CO 20 (50.0) 20 (50.0)
Oakland, CA 34 (50.0) 34 (50.0)
Los Angeles, CA 17 (50.0) 17 (50.0)
Sex
Male 33 (39.8) 50 (60.2) 0.01
Female 64 (57.7) 47 (42.3)
Age
<60 36 (62.1) 22 (37.9) <0.01
60-69 42 (53.9) 36 (46.2)
70+ 19 (32.8) 39 (67.2)
Race/Ethnicity
Non-Hispanic White 32 (43.2) 42 (56.8) 0.14
Black 35 (60.3) 23 (39.7)
Hispanic 30 (48.4) 32 (51.6)
Glucose tolerance at
1992-94
Normoglucose 54 (49.5) 55 (50.5) 0.68
Impaired glucose tolerance 20 (57.1) 15 (42.9)
Type II diabetes mellitus 23 (47.9) 25 (52.1)
BMI (kg/m2) at 2002-2004
Normal (<25kg/m2) 54 (50.0) 54 (50.0) 1.00
Overweight (25-29.9 kg/m2) 19 (50.0) 19 (50.0)
Obese (30 + kg/m2) 24 (50.0) 24 (50.0)
Smoking at 2002-2004
Never 51 (53.7) 44 (46.3) 0.32
Ever 46 (46.7) 53 (53.5)
Self reported previous
screening
None 34 (54.8) 28 (45.2) <0.01
Yes, without polyp 56 (54.9) 46 (45.1)
Yes, with polyp 7 (23.3) 23 (76.7)
NSAID use
None or Don’t Know 33 (45.2) 40 (54.8) 0.30
Yes 64 (52.9) 57 (47.1)
Population data for participants included in the Insulin Resistance
Atherosclerosis Study (IRAS). Details of the design and recruitment have been
published previously [29]. Numbers in the parentheses represent the
percentage of the total individuals included in each category. Statistical
significance was determined used Chi-squared test.
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for potential confounders. Unadjusted and adjusted odds
ratios and 95% confidence intervals (CI) were estimated.
Linear trends were calculated by treating the categorical
variable as continuous in the logistic models. Intercooled
Stata version 11 (StataCorp, Stata Statistical Software:
Release 11, College Station, TX, StataCorp LP, 2009) was
used to conduct all analyses based on 2-sided statistical
tests with an alpha level of 0.05.
Pair-wise correlations between cytokine levels were
done by either Pearson or Spearman correlation coeffi-
cients, depending on normality of distributions of each
cytokine samples measured by D’Agostino’s K2 test
[32,33]. The parametric Pearson method was only used
in cases when both samples in the compared pair were
normally distributed. Otherwise, the samples were com-
pared by a Spearman non-parametric correlation test.
Correlations were called significant using the 0.05




Among the 194 IRAS Colon Study participants included
in this analysis, older men who had previously reported
being screened for colorectal cancer were significantly
associated with adenoma prevalence in the bivariate ana-
lysis (Table 1). No significant associations were observed
between adenoma status and center, race/ethnicity, glu-
cose tolerance status, BMI, NSAID use, and smoking
status. The participants in our study did not report hav-
ing predisposing pro-inflammatory conditions such as
IBD or chronic infections; however, we observed that
factors known to be associated with elevated inflamma-
tion (advanced age; [22,34]) were significantly associated
with the presence of adenomas (Table 1).
Normal biological relationships are observed in serum
cytokines used for analysis
Pairwise correlation analysis was used to determine if the
expected relationships existed between cytokines assayed
in this study in the IL-7 positive samples, which were used
to assay if elevated cytokine profiles were observed in par-
ticipants with adenomas relative to those without an aden-
oma. Interferon gamma, which is a potent inducer of
chemokines [35], tracked significantly with chemokines
such as MIP-1β (0.4095, Figure 1). The cytokine IL-12p70
is a potent inducer of IFN-γ production from T-
lymphocytes [36] and antagonizes the actions of the
anti-inflammatory cytokine IL-10 [37]. A modest positive
correlation was observed between IL-12p70 and IL-10
(0.2928, Figure 1), and a stronger correlation was observed
between IL-12p70 and IFN-γ (0.4895, Figure 1). The hall-
mark proinflammatory cytokines IL-6 and IL-1β alsosignificantly tracked together (0.5272, Figure 1). Further-
more, the Th1-associated cytokine TNF-α did not track
with the Th2-skewing cytokine IL-4 (Figure 1). Based on
Figure 1 Correlation between cytokines present in the serum of study participants. Spearman or Pearson correlation criteria were used in
each pairwise comparison based on the distributions of values in each cytokine pair at the significance level of 0.05; only significantly correlated
values are presented. Colourwash panels show intensity of FDG uptake and PF.
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serum samples, we determined if the increased inflamma-
tion was associated with the presence of adenomas.
Adenomas are not associated with altered serum cytokine
levels
Analyses of the proinflammatory cytokines TNF-α, IL-6,
and IL-1β in the serum of participants with colorectal ad-
enomas compared to non-adenoma controls (Figure 2A)
revealed that the presence of adenomas do not lead to sys-
temic elevation in the levels of these cytokines. In
addition, we observed similar serum chemokine levels in
participants with adenomas present at the time of the col-
onoscopy relative to participants without detectable aden-
omas (Figure 2B). Furthermore, cytokines that are known
to promote (IL-12, IFN-γ, and IL-2) or regulate (IL-10, IL-
4, and IL-17) T-cell polarization and differentiation were
similar in the serum of individuals with and without de-
tectable adenomas (Figure 2C and D).
Although serum cytokines levels were not significantly
increased in participants with adenomas relative to non-
adenoma controls, we observed that the average concen-
trations for the T-cell activating cytokines IL-12p70
(non-adenoma mean of 24.05 pg/mL; adenoma mean of
10.16 pg/mL), IFN-γ (non-adenoma mean of 29.28 pg/mL; adenoma mean of 15.13 pg/mL), and IL-2 (non-ad-
enoma mean of 7.44 pg/mL; adenoma mean of 3.56 pg/
mL), while not significantly different, were lower in pa-
tients with adenomas relative to control subjects. Fur-
thermore, when we adjusted the data for age, sex, and
previous screening, we observed that the levels of the
chemokine RANTES was significantly lower in patients
with adenomas relative to controls (0.04, Table 2). These
data indicate that minor changes in systemic inflamma-
tory status may be associated with colorectal adenomas,
but the robust induction of cytokines is not associated
with the development of these conditions. These results
were confirmed in the logistic regression analysis which
revealed that no association existed between colorectal
adenomas and GM-CSF, IFN-γ, IL-10, IL-12p70, IL-17A,
IL-1β, IL-2, IL-4, IL-6, IL-7, MCP-1, MIP-1β, and VEGF
after adjustment for age, sex, and previous colorectal
screening (Table 2).
Discussion
Whether inflammation causes CRC or is induced by
CRC is still an area of heavy investigation; however, what
is well established is that inflammation increases as dis-
ease progresses [18,19,23]. Unlike the clear correlation
that exists between advanced-stage CRC development
Figure 2 Healthy patients and those with adenomas exhibit similar serum cytokine profiles. Serum samples from healthy individuals and
those with adenomas were subjected to cytokine analysis using the Human Cytokine/ Chemokine Magnetic Bead Panel protocol from Milliplex®.
Shown are the concentrations of selected proinflammatory cytokines (A), chemokines (B), cytokines that activate T-cell responses (C), and those
that regulate T-cell polarization/ differentiation (D). The levels of IL-7 in all of the analyzed samples were not significantly different between
non-adenoma and adenoma positive study participants (data not shown). MIP-1β and GM-CSF were undetectable in most samples and found
only at low levels in samples that were included in the cytokine analysis (data not shown).
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in promoting the formation of high-risk conditions such
as adenomas is unclear [3,7,38]. Our results did not find
a correlation between adenoma status and alterations in
circulating cytokine and chemokine levels, which is con-
sistent with other reports showing that the presence of
adenomas do not alter systemic cytokine and chemokine
profiles [3,7,24].
Although we did not observe significant alterations in
serum cytokine levels in study participants with aden-
omas relative to controls, we did observe an overall de-
crease in the serum levels of IL-2, IL-12p70, and IFN-γ
in participants with adenomas as compared to those
without an adenoma. In the Bobe et al. study, the pres-
ence of adenomas correlated with reduced serum IL-2
levels which was associated with an increase in adenoma
recurrence [24]. Furthermore, NSAIDs usage correlates
with reduced adenoma and CRC incidence [7,39,40].
Moreover, once pre-malignant lesions are detected,
NSAIDs and flavonols have demonstrated protective ef-
fects against the transition from colorectal adenomas to
advanced stage CRC [25,39,41-43] which are thought to
be mediated largely by their anti-inflammatory proper-
ties [43]. These results indicate that inflammation may
play a role in the development adenomas; however, ourresults and others suggest that the development of pre-
malignant stages of disease is not associated with sub-
stantial changes in systemic inflammation.
One limitation of this study is due to the large amount
of samples that were below the detectable level of the
assay which lead to a relatively small sample size thus
reducing the power of the study to detect statistically
significant associations. However, this study had at least
80% power to detect an odds ratio of 0.17 or 2.75. Fur-
thermore, by utilizing only those samples from partici-
pants in which IL-7 could be reliability measured, we are
confident that degradation was not an issue with the in-
cluded samples. We assume that the removal of de-
graded samples would be non-differential and therefore
not bias the outcome of the study.
Conclusion
By using a stringent quality control method to exclude the
analysis of potentially degraded samples, we have con-
cluded that there is no large association between colorectal
adenomas status and systemic levels of proinflammatory
(TNF-α, IL-6, IL-1β) or T-cell polarizing (IL-12, IL-2,
IL-10, IL-4, IL-17, IFN-γ) cytokines among a subset of par-
ticipants from the IRAS Colon Study. Furthermore, no as-
sociation between adenoma status and alterations in
Table 2 Associations between cytokines and colorectal









L 67/124 (54.0) 1.00 1.00
M 17/37 (46.0) 0.72 (0.35 1.51) 0.83 (0.38 1.82)
H 13/33 (39.4) 0.55 (0.25 1.21) 0.70 (0.30 1.62)
p for trend 0.38
Interferon gamma
L 37/77 (48.1) 1.00 1.00
M 42/71 (59.2) 1.57 (0.82 3.00) 1.35 (0.67 2.72)
H 18/46 (39.1) 0.69 (0.33 1.46) 0.77 (0.35 1.69)
p for trend 0.67
IL-10
L 55/112 (49.1) 1.00 1.00
M 18/38 (47.4) 0.93 (0.45 1.95) 0.91 (0.41 2.00)
H 24/44 (54.6) 1.24 (0.62 2.50) 1.45 (0.69 3.08)
p for trend 0.40
IL-12p70
L 50/103 (48.5) 1.00 1.00
M 35/57 (61.4) 1.69 (0.87 3.26) 1.86 (0.92 3.76)
H 12/34 (35.3) 0.58 (0.26 1.29) 0.59 (0.25 1.42)
p for trend 0.68
IL-17A
L 82/152 (54.0) 1.00 1.00
M 5/19 (26.3) 0.30 (0.10 0.89) 0.42 (0.14 1.30)
H 10.23 (43.5) 0.66 (0.27 1.59) 0.83 (0.33 2.13)
p for trend 0.40
IL-18
L 67/127 (52.8) 1.00 1.00
M 12/31 (38.7) 0.57 (0.25 1.26) 0.81 (0.34 1.96)
H 18/36 (50.0) 0.90 (0.43 1.88) 1.09 (0.50 2.41)
p for trend 0.93
IL-2
L 37/132 (50.8) 1.00 1.00
M 15/31 (48.4) 0.91 (0.42 1.99) 1.25 (0.53 2.96)
H 15/31 (48.4) 0.91 (0.42 1.99) 1.14 (0.49 2.62)
p for trend 0.67
IL-4
L 56/117 (47.9) 1.00 1.00
M 24/42 (57.1) 1.45 (0.71 2.96) 1.83 (0.84 3.98)
H 17/35 (48.6) 1.03 (0.48 2.19) 1.33 (0.59 3.02)
p for trend 0.29
IL-6
L 53/117 (45.3) 1.00 1.00
Table 2 Associations between cytokines and colorectal
adenomas among participants in the IRAS Colon Study
(Continued)
M 29/46 (63.0) 2.06 (1.02 4.15) 2.57 (1.19 5.54)
H 15/31 (48.4) 1.13 (0.51 2.50) 1.35 (0.58 3.19)
p for trend 0.17
IL-7
L 40/73 (54.8) 1.00 1.00
M 28/60 (46.7) 0.72 (0.36-1.43) 0.59 (0.28-1.24)
H 29/61 (47.5) 0.75 (0.38-1.48) 0.60
p for trend
MIP-1β
L 22/53 (41.5 1.00 1.00
M 53/87 (60.9) 2.20 (1.10-4.40 2.69 (1.25-5.80)
H 22/54 (4.7) 0.97 (0.45-2.09) 1.25 (0.54-2.91)
p for trend 0.65
RANTES
L 46/79 (58.2) 1.00 1.00
M 32/64 (50.0) 0.72 (0.37-1.39) 0.66 (0.33-1.35)
H 19/51 (37.3) 0.43 (0.21-0.88) 0.46 (0.21-0.99)
p for trend 0.04
VEGF
L 13/19 (68.4) 1.00 1.00
M 40/86 (46.5) 0.40 (0.14-1.15) 0.42 (0.14-1.28)
H 44/89 (49.4) 0.45 (0.46-1.29) 0.62 (0.20-1.88)
p for trend 0.97
TNFα
L 31/64 (48.9) 1.00 1.00
M 37/68 (54.4) 1.27 (0.64-2.51) 1.27 (0.64-2.52)
H 29/62 (46.8) 0.93 (0.46-1.88) 1.14 (0.55-2.35)
p for trend 0.54
Tertiles were generated with those undetectable as the referent value and
then the other tertiles based on the median of cytokines values from
participants with normal colonoscopies except for those in bold. Those in bold
had no or only a few undetectable values so tertiles were based on the
distribution in normal point. Multivariate unconditional logistic regression was
used to evaluate the association between adenoma prevalence and the
categories of each cytokine individually while controlling for potential
confounders. Low (denoted by L), medium (denoted by M), and high (denoted
by H) cytokine concentrations are indicated. Statistically significant results
indicated in bold type.
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this study. Our observations are consistent with other
studies, further suggesting that the induction of robust sys-
temic inflammation is not associated with the presence of
detectable colorectal adenomas; however, small associa-
tions are possible. In these studies we did not address the
association between adenoma status and local alterations
in the colonic microenvironment; therefore, changes in
local inflammation and alterations of the gut microbiome
should be explored in future studies.
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